Nektar Therapeutics (NKTR) shares soared 41.95 percent, up $15.55, to $52.62 on Tuesday after the company reported positive results from the 36-week blinded maintenance period of its Phase 2b REZOLVE-AD study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.
The stock is trading at $52.62, compared with a previous close of $37.07. Shares opened at $47.19 and traded between $47.05 and $55.43 during the session on the Nasdaq. The last bid was $46.03 for 100 shares, while the ask stood at $60.41 for 200 shares. Trading volume reached about 5.05 million shares, sharply higher than the average volume of about 0.77 million.
Nektar Therapeutics shares have traded within a 52-week range of $6.45 to $66.92.
The study showed sustained clinical responses during the maintenance phase following the induction period, supporting the potential of the company's regulatory T-cell-targeted biologic therapy.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.